Cell lines

Bladder smooth muscle cells, CEM human leukemic T cells

Preparation method

The solubility of this compound in DMSO is >24.1mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0.1 nM-1 μM

Applications

In bladder smooth muscle cells, solifenacin inhibited Ca2+ mobilization induced by 10 μM carbachol in a concentration-dependent manner. In CEM human leukemic T cells, YM905 (10 nM to 10 μM) significantly reduced the number of cells responding to 10 μM Oxo-M. YM905 attenuated the upregulation of c-fos mRNA expression induced by 10 μM Oxo-M, though it had no effect on basal expression of c-fos mRNA at 1 or 10 μM.

Animal models

Female Wistar rats, Mice

Dosage form

Intravenous injection, 0.03-1 mg/kg

Application

YM905 (0.03-1 mg/kg, i.v.) dose-dependently and significantly suppressed increases in intravesical pressure. YM905 (0.1 mg/kg, i.v.) had no effect on salivary secretion. YM905 (i.v.) showed more than about 50% inhibition at 0.3 mg/kg. YM905 showed significantly more potent inhibition of bladder responses over salivary responses, with ID30 and ID50 values indicating 6.5- and 3.7-fold greater selectivity for urinary bladder, respectively. YM905 potently inhibited restraint stress-induced fecal pellet output in fed rats (ED50: 4.0 mg/kg) and diarrhea in fasted rats (ED50: 1.7 mg/kg). YM905 inhibited 5-hydroxytryptamine (5-HT)-, prostaglandin E2- and castor oil-induced secretory diarrhea in mice (ED50: 5.5, 14 and 6.3 mg/kg, respectively), but showed no significant effect on cholera toxin-induced intestinal secretion in mice. YM905 (3, 10 mg/kg) reversed morphine-decreased postprandial defecation in ferrets, a model of spastic constipation.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Solifenacin succinate is a quinuclidine and tetrahydroisoquinoline derivative and selective M3 muscarinic antagonist. It is used as a urological agent in the treatment of overactive bladder[1].

M3 muscarinic receptor is a muscarinic acetylcholine receptor encoded by the human gene CHRM3. Muscarinic M3 receptors are involved in various cellular responses, including breakdown of phosphoinositides, inhibition of adenylate cyclase and modulation of potassium channels through the action of G proteins[2].

In vitro: In radioligand receptor binding assay, the Kivalues of solifenacin for human muscarinic M1, M2, M3, M4and M5receptors were 26, 170, 12, 110 and 31 nM, respectively. In isolated rat urinary bladder, solifenacin competitively antagonized carbachol-induced contractions, with a pA2value of 7.44±0.09[3].In bladder smooth muscle cells and salivary gland cells isolated from rats, solifenacin and the other antimuscarinic drugs inhibited carbachol-induced increases in intracellular Ca2+levels in a concentration-dependent manner. ThepKi was 8.12for bladder smooth muscle cells, 3.6-fold more potent than that for salivary gland cells (pKi=7.57) [1].

In vivo: In anesthetized rats, solifenacin dose-dependently inhibited carbachol-induced intravesical pressure elevation and salivary secretion, and exhibited selectivity (3.7- to 6.5-fold) for urinary bladder over salivary gland [1]. In anesthetized rats, solifenacin and oxybutynin increased the maximum bladder capacity in a dose-dependent manner and also decreased the maximum intravesical pressure [3].In healthy young men, multidose study evaluated doses. In the single-dose of solifenacin succinate (5-, 10-, 20-, and 30-mg), mean time to maximal concentration and elimination half-life ranged from 3.3 to 4.8 and from 40.2 to 57.6 hours, respectively.In the multidose study, the ranges were 2.9 to 5.8 and 45.0 to 64.8, respectively. The single-dose administration was well tolerated. The common adverse events were dry mouth, blurred vision, and headache [4].

Clinical trials: In this phase 3 trial in patients with symptoms related to overactive bladder, treatment with solifenacin (5 mg or 10 mg, once daily) significantly improved all the major symptoms of overactive bladder including urgency, frequency and incontinence. Solifenacin (10 mg) decreased the frequency of nocturia. Solifenacin therapy has been associated with a favorable tolerability profile and low incidence of dry mouth, especially at the 5 mg starting dose [5].

References:
[1]. Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats[J]. European journal of pharmacology, 2004, 492(2): 243-250.
[2]. Yang J, Williams J A, Yule D I, et al. Mutation of carboxyl-terminal threonine residues in human m3 muscarinic acetylcholine receptor modulates the extent of sequestration and desensitization[J]. Molecular pharmacology, 1995, 48(3): 477-485.
[3]. Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents[J]. Biological and Pharmaceutical Bulletin, 2007, 30(1): 54-58.
[4]. Smulders R A, Krauwinkel W J, Swart P J, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men[J]. The Journal of Clinical Pharmacology, 2004, 44(9): 1023-1033.
[5]. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder[J]. The Journal of urology, 2004, 172(5): 1919-1924.